Redmile Group LLC boosted its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 281.7% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 140,243 shares of the biotechnology company’s stock after buying an additional 103,500 shares during the period. Redmile Group LLC owned about 0.26% of Aurinia Pharmaceuticals worth $1,029,000 as of its most recent filing with the SEC.
Other institutional investors also recently bought and sold shares of the company. UBS Group AG boosted its position in Aurinia Pharmaceuticals by 13.6% in the first quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock worth $824,000 after buying an additional 13,405 shares in the last quarter. Geode Capital Management LLC bought a new position in Aurinia Pharmaceuticals during the first quarter worth $187,000. Monashee Investment Management LLC bought a new position in Aurinia Pharmaceuticals during the first quarter worth $1,835,000. FMR LLC bought a new position in Aurinia Pharmaceuticals during the first quarter worth $42,928,000. Finally, Credit Agricole S A bought a new position in Aurinia Pharmaceuticals during the first quarter worth $1,393,000. Institutional investors own 29.26% of the company’s stock.
Aurinia Pharmaceuticals Inc (AUPH) traded up 9.97% during trading on Tuesday, reaching $6.73. 3,537,704 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $6.72 and a 200 day moving average price of $5.19. Aurinia Pharmaceuticals Inc has a 52 week low of $1.74 and a 52 week high of $10.54. The firm’s market capitalization is $560.42 million.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Monday, May 15th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.08. Aurinia Pharmaceuticals had a negative net margin of 48,278.23% and a negative return on equity of 50.53%. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.05 million. Equities research analysts forecast that Aurinia Pharmaceuticals Inc will post ($0.44) earnings per share for the current fiscal year.
WARNING: This piece was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://sportsperspectives.com/2017/06/20/redmile-group-llc-has-1-03-million-position-in-aurinia-pharmaceuticals-inc-auph.html.
A number of equities analysts have weighed in on AUPH shares. HC Wainwright reduced their price objective on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, May 18th. Cantor Fitzgerald started coverage on shares of Aurinia Pharmaceuticals in a research report on Monday, April 10th. They set an “overweight” rating and a $14.00 price objective for the company. FBR & Co restated an “outperform” rating on shares of Aurinia Pharmaceuticals in a research report on Tuesday, April 11th. Canaccord Genuity restated a “buy” rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, March 3rd. Finally, Leerink Swann upped their price objective on shares of Aurinia Pharmaceuticals from $7.00 to $11.00 and gave the stock an “outperform” rating in a research report on Thursday, March 2nd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $9.64.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.